Novavax (NASDAQ:NVAX) Stock Moved Up to Buy by Wall Street Zen

Key Points

• Wall Street Zen upgraded Novavax from Hold to Buy, though analyst sentiment remains mixed: MarketBeat’s consensus rating is Hold with a $12.33 price target.
• Novavax reported a third-quarter loss of $0.19 per share, beating estimates, and revenue of $68.3 million, also above expectations; revenue was down 3% year over year.
• The company raised its 2026 revenue outlook, largely reflecting a $125 million Sanofi milestone, and said its cash runway extends into 2029. However, profitability is now targeted for 2029.

Novavax (NASDAQ:NVAX - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research report issued on Saturday, Wall Street Zen reports.

A number of other analysts also recently commented on NVAX. Citigroup reissued a "sell" rating and set a $8.00 price objective (up from $7.00) on shares of Novavax in a report on Thursday, October 15th. Weiss Ratings reiterated a "sell (d)" rating on shares of Novavax in a research note on Monday. B. Riley Financial reissued a "buy" rating and set a $16.00 target price (down from $18.00) on shares of Novavax in a research report on Friday. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Novavax in a research note on Tuesday, October 27th. Finally, Zacks Research cut Novavax from a "strong-buy" rating to a "hold" rating in a report on Thursday, August 6th. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and three have issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $12.33.

Novavax Price Performance

NVAX opened at $10.78 on Friday. The firm has a market capitalization of $1.78 billion, a price-to-earnings ratio of -23.43 and a beta of 2.65. Novavax has a fifty-two week low of $6.20 and a fifty-two week high of $13.39. The company's 50 day moving average price is $10.56 and its two-hundred day moving average price is $9.35.

Novavax (NASDAQ:NVAX - Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The biopharmaceutical company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.16. The firm had revenue of $68.30 million for the quarter, compared to the consensus estimate of $50.42 million. Novavax had a negative return on equity of 14.82% and a negative net margin of 59.87%. The company's quarterly revenue was down 3.0% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.25) earnings per share. As a group, equities research analysts predict that Novavax will post -0.38 EPS for the current year.

Hedge Funds Weigh In On Novavax

A number of hedge funds and other institutional investors have recently made changes to their positions in NVAX. Russell Investments Group Ltd. raised its position in shares of Novavax by 5.1% during the 3rd quarter. Russell Investments Group Ltd. now owns 94,969 shares of the biopharmaceutical company's stock valued at $1,027,000 after buying an additional 4,632 shares during the period. Fulcrum Asset Management LLP acquired a new stake in shares of Novavax during the 3rd quarter valued at $181,000. Allspring Global Investments Holdings LLC grew its stake in Novavax by 4.5% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 27,820 shares of the biopharmaceutical company's stock valued at $295,000 after buying an additional 1,207 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in Novavax during the third quarter valued at approximately $91,000. Finally, China Universal Asset Management Co. Ltd. raised its holdings in Novavax by 15.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 30,096 shares of the biopharmaceutical company's stock valued at $326,000 after acquiring an additional 3,926 shares during the period. Institutional investors own 53.04% of the company's stock.

Key Stories Impacting Novavax

Here are the key news stories impacting Novavax this week:

• Positive Sentiment: Novavax reported a Q3 loss of $0.19 per share, narrower than analysts’ expected $0.35 loss, while revenue of $68.3 million topped estimates of about $50.4 million. The loss also improved from $0.62 per share a year earlier. Article: Novavax Reports Q3 Loss, Tops Revenue Estimates
• Positive Sentiment: The company raised its 2026 revenue outlook to $385 million–$415 million, or $400 million at the midpoint—about $145 million higher than its prior framework. A $125 million milestone from Sanofi, earned after a Phase 3 trial launch, accounts for much of the increase. Novavax also reduced operating expenses and said its cash runway extends into 2029. Article: Novavax boosts 2026 revenue forecast as licensing deals pay off
• Neutral Sentiment: B. Riley reaffirmed its Buy rating, though it lowered its price target to $16 from $18. The reduced target tempers the otherwise positive analyst stance. Article: B. Riley stock recommendations
• Negative Sentiment: Investors may be focused on Novavax pushing its profitability target out to 2029. Q3 revenue was still down 3% year over year, and the higher 2026 outlook depends substantially on the Sanofi milestone, raising questions about the durability of revenue growth. Article: Novavax pushes profitability target to 2029, shares dip

Novavax Company Profile

Novavax, Inc is a biotechnology company focused on developing and commercializing vaccines for infectious diseases. The company uses recombinant protein nanoparticle technology and its proprietary Matrix-M adjuvant to develop vaccines designed to stimulate targeted immune responses.

Novavax's principal commercial product is Nuvaxovid, also known as the Novavax COVID-19 vaccine, a protein-based vaccine developed to help prevent COVID-19. The vaccine has been authorized or approved in various markets, subject to local regulatory requirements, and the company has worked with governments, public-health organizations, and pharmaceutical partners to support its distribution internationally.

Founded in 1987, Novavax is headquartered in Gaithersburg, Maryland.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.